2022
DOI: 10.1016/s1473-3099(22)00221-3
|View full text |Cite
|
Sign up to set email alerts
|

Review of 2022 WHO guidelines on the control and elimination of schistosomiasis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
98
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
4
3
1

Relationship

1
7

Authors

Journals

citations
Cited by 115 publications
(99 citation statements)
references
References 38 publications
1
98
0
Order By: Relevance
“…Calls to develop specific programmatic guidance on how to achieve and maintain EPHP 6,33 have yet to be heeded. 16,17 Unfortunately, we believe an outdated framework for EPHP remains in place and a large disconnect remains between existing practice and recent findings. A move away from PHI-based targets is needed to align with current knowledge of morbidity.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Calls to develop specific programmatic guidance on how to achieve and maintain EPHP 6,33 have yet to be heeded. 16,17 Unfortunately, we believe an outdated framework for EPHP remains in place and a large disconnect remains between existing practice and recent findings. A move away from PHI-based targets is needed to align with current knowledge of morbidity.…”
Section: Discussionmentioning
confidence: 99%
“…15 Furthermore, WHO's treatment strategy for schistosomiasis mass drug administration is determined by the prevalence and does not use PHI. 16,17 Collecting intensity data to determine whether a PHI threshold has been reached involves a larger sample to be tested. Intensity determinations also require the counting of eggs and are more prone to measurement error than a binary decision for prevalence.…”
Section: Infection Prevalence Not Phimentioning
confidence: 99%
“…POC-CCA accuracy has been found to vary depending on production batch, raising questions regarding production quality control and calls for the optimisation and standardisation of production [6062]. This is of particular relevance if POC-CCA is to become reliable a tool with which to determine whether to treat human and livestock populations [2–4].…”
Section: Discussionmentioning
confidence: 99%
“…Within this, point-of-care diagnostic testing is particularly needed wherever there is a necessity for a fast diagnostic outcome that is independent from sophisticated, time-consuming, labour-intense and/or expensive laboratory procedures [1]. This need may be most exemplified for the neglected tropical and zoonotic diseases (NTDs/NZDs), as clearly stressed within the new World Health Organization’s (WHO) NTD Roadmap for 2021-2030 [2] and revised WHO Guideline for the control and elimination of human schistosomiasis, most notably that of recommendation 6 [3, 4].…”
Section: Introductionmentioning
confidence: 99%
“…Among them, the Schistosoma genus is the most important in terms of human health and social-economic impacts. Human schistosomiasis affects about 250 million people in about 78 countries worldwide, with the largest disease burden throughout sub-Saharan Africa [5]. The Schistosoma genus is composed of about 23 recognized species with at least 19 species that infect livestock and wild animals [6].…”
Section: Introductionmentioning
confidence: 99%